Table 1 Patient demographics and baseline characteristics.

Patient demographics and baseline characteristics.. FPG, fasting plasma glucose.

CharacteristicTTP399 (400 mg) (n = 50)TTP399 (800 mg)
(n = 42)
Sitagliptin
(n = 49)
Placebo
(n = 48)
Mean age, y (±SD)52.8 ± 10.757.0 ± 8.555.1 ± 9.655.7 ± 11.7
Male, n (%)23 (46.0)22 (52.4)29 (59.2)27 (56.3)
White, n (%)42 (84.0)32 (76.2)41 (85.4)39 (81.3)
Mean weight, kg (±SD)94.1 ± 19.492.3 ± 24.295.8 ± 19.091. 6 ± 19.8
Mean body mass index, kg/m2 (±SD)33.3 ± 5.432.1 ± 5.833.1 ± 5.732.4 ± 5.6
Mean HbA1c, % (±SD)7.9 ± 0.78.1 ± 0.78.1 ± 0.77.9 ± 0.7
Mean metformin dose, mg (±SD)1652 ± 4511625 ± 5181647 ± 4451693 ± 513
Mean years since diagnosis (±SD)7.3 ± 6.27.7 ± 5.48.3 ± 6.88.2 ± 6.0
FPG, mg/dl (±SD)163.9 ± 39.0162.8 ± 44.0163.4 ± 41.1167.4 ± 36.3
Glucagon, ng/liter (±SD)40.6 ± 33.442.5 ± 34.253.1 ± 55.444.6 ± 26.5
GLP-1, ng/liter (±SD)4.5 ± 5.94.3 ± 6.98.3 ± 16.46.5 ± 9.9
LDL-C, mg/dl (±SD)97.7 ± 34.085.5 ± 24.495.6 ± 37.484.0 ± 30.9
HDL-C, mg/dl (±SD)48.8 ± 13.652.9 ± 13.846.4 ± 11.648.8 ± 14.8
TG, mg/dl (±SD)185.4 ± 111.0157.5 ± 104.9195.8 ± 143.6163.8 ± 96.8
Non–HDL-C, mg/dl (±SD)134.7 ± 37.3116.4 ± 31.7134.1 ± 48.8117.0 ± 36.1